Manchester United has reported an annual net loss of £43m, widening by £10m from the prior year, while total debt rose by £95m to £583m. The club said record revenue of £677.6m was supported by a £33.9m increase in broadcasting income, even as financial pressure persisted. It also attributed the loss largely to weaker broadcasting revenue and ticket sales linked to the absence of European competition.

Grab executives bought more than $30 million worth of company shares this week after the stock slid to a more than three-year low of $2.74 following its deal to acquire buy-now-pay-later provider Atome Financial. The company also said it plans to buy back around $900 million shares over the next 12 months, but the September 15 announcements failed to lift the stock. Grab shares have tumbled 50% over the past year.

Investor Michael Burry has disclosed a long position tied to copper producer Ero Copper. Expectations for further gains in the metal have been bolstered by supply constraints, falling inventories and limited new mine discoveries. Copper on the London Metal Exchange has risen 18% so far this year, and global mined copper output could decline this year for the first time since 2017, according to Axis Securities.

Novo Nordisk has outlined a long-term strategy that includes launching five blockbuster drugs by 2030 and generating $23 billion in pipeline revenue by 2035 to offset potential sales erosion after Wegovy’s patent expiry. The plan hinges on a new wave of weight-loss tablets and improved combinations of diabetes and obesity treatments aimed at greater weight loss with fewer side effects. It also includes an expansion into areas such as blood and endocrine disorders. Investors remained unconvinced, sending the shares down 8% on Monday.

International oil prices fell for a sixth straight session, with Brent down about 1% to $98.30 and WTI down 1.4% to $89.49. U.S.-Iran talks held at the United Nations, alongside the restart of a previously disrupted Saudi pipeline, eased concerns over potential Middle East supply disruptions. Saudi Aramco plans to restore pipeline flows to roughly 4 million barrels per day (bpd) within a few weeks.

A U.S. FDA advisory panel is set to vote on whether to recommend authorization of Grail’s Galleri blood test, which the company says can detect up to 50 types of cancer and costs $949. The test is under expedited FDA review, and an approval could make it the first FDA-authorized multicancer screening blood test and potentially open the door to insurance reimbursement. Abbott is also pursuing FDA clearance for a competing multicancer test.

Saudi Arabia has brought a 1,200-kilometre oil pipeline back into operation, allowing crude to be shipped directly to the Red Sea and bypass the Strait of Hormuz. The move eased concerns about supply disruptions. Global oil prices at one point fell by more than US$2 a barrel on Tuesday.

SAP reported Q2 2026 results led by €6.28B ($7.15B USD) Cloud Revenue Growing 22%, and SAP shares moved -1.59% in the completed reaction session. The analysis explains the earnings mix, financial outlook and three-month technical levels.